CJC-1295 + Ipamorelin

Overview

Torsena supplies research-grade peptide preparations to qualified laboratories across the European Union. This product contains CJC-1295 without DAC, also known as Modified GRF (1-29), co-lyophilised with Ipamorelin at equal ratio by weight. Furthermore, we hold stock in Europe, so orders ship without intra-EU customs delay.

Lot & Supply Format

• Component purity. Each peptide is sourced at typically ≥99% purity against its own raw-material CoA, prior to blending.
• Formulation. Mannitol-free, so no bulking agents or buffer salts dilute the material.
• Presentation. Co-lyophilised preparation, sealed in glass research vials.
• Composition. Equal ratio by weight, namely 5mg of each per 10mg vial.
• Shipping. Dispatched from Europe, and always with temperature-appropriate packaging.

What is the CJC-1295 + Ipamorelin preparation?

This preparation combines two growth hormone axis peptides that act on different receptors. CJC-1295 without DAC agonises the GHRH receptor, while Ipamorelin agonises GHS-R1a, the ghrelin receptor. Both converge on pituitary somatotroph signaling, but they arrive by separate routes.

CJC-1295 without DAC (Modified GRF 1-29). A 29-residue analog of growth hormone-releasing hormone carrying four amino acid substitutions. It signals through the adenylyl cyclase, cAMP and PKA cascade. Half-life is roughly 30 minutes, so it produces discrete pulses rather than sustained elevation.

Ipamorelin. A five-residue pentapeptide and a selective GHS-R1a agonist. It signals through intracellular calcium mobilisation and PKC. Notably it is characterised as highly selective, with minimal activation of ACTH, cortisol or prolactin pathways, which is what distinguishes it from earlier growth hormone secretagogues.

Because the two receptors use different second messenger systems, concurrent application produces a combined response that published work describes as exceeding the sum of either agonist alone. Consequently this pairing is among the most referenced in growth hormone axis research.

Supplied exclusively for in-vitro and ex-vivo research by qualified laboratories. Not intended for human or animal administration.

CJC-1295: With DAC and Without

Two structurally distinct compounds ship under the CJC-1295 name, and vendor listings conflate them constantly. This preparation contains the non-DAC form.

Property	CJC-1295 no DAC	CJC-1295 with DAC
Also called	Mod GRF 1-29	CJC-1295 DAC
Length	29 residues	30 residues
Molecular weight	~3368 Da	~3647 Da
Molecular formula	C152H252N44O42	C165H269N47O46
Albumin binding	None	Via maleimidopropionyl-Lys
Half-life	~30 minutes	Days
Receptor activation	Pulsatile	Sustained

The molecular weight on a Certificate of Analysis distinguishes them unambiguously, since a 279 Da difference is far outside any rounding or hydration variance. Note that CAS 863288-34-0 appears against both forms across the market, so treat the CAS as unreliable here and work from the mass instead.

The Four Substitutions

Modified GRF (1-29) differs from native GHRH(1-29) at four positions, and each change addresses a specific degradation route.

Position	Native	Modified	Purpose
2	L-Ala	D-Ala	Blocks DPP-IV cleavage
8	Asn	Gln	Prevents asparagine deamidation
15	Gly	Ala	Enhances bioactivity
27	Met	Leu	Removes oxidation-prone methionine

The Leu27 substitution has a consequence worth noting for handling. Because it removes the only methionine in the sequence, Mod GRF (1-29) contains no sulfur, which is why the formula carries no S. Therefore it does not need the air-exposure precautions that methionine-containing peptides require.

Complementary Receptor Signaling

Parameter	CJC-1295 no DAC	Ipamorelin
Target receptor	GHRH-R	GHS-R1a
Receptor class	Class B GPCR	Class A GPCR
Second messenger	cAMP, PKA	Ca²⁺, PKC
Peptide length	29 amino acids	5 amino acids
Molecular weight	3367.9 Da	711.85 Da
Molecular formula	C152H252N44O42	C38H49N9O5
Selectivity	GHRH-R specific	GHS-R1a selective
CAS number	863288-34-0	170851-70-4

The different second messenger systems are the mechanistic basis for using both together, since cAMP-PKA and calcium-PKC signaling converge on somatotroph output without competing for the same pathway.

Research Applications

• Somatotroph signaling. Cultured anterior pituitary cell assays, and likewise GH secretion endpoints.
• Receptor crosstalk. Dual agonist protocols, particularly where the question is pathway convergence.
• Pulsatility studies. The short half-life of the non-DAC form makes it suited to work on discrete pulse timing.
• Comparative secretagogue pharmacology. GHRH-R against GHS-R1a, namely for selectivity profiling.

Preparation specifications

Product name	CJC-1295 (no DAC) + Ipamorelin research preparation
Composition	Equal ratio by weight, 5mg each per 10mg vial
Component 1	CJC-1295 no DAC / Mod GRF 1-29, C152H252N44O42, 3367.9 Da
Component 2	Ipamorelin, C38H49N9O5, 711.85 Da
CAS numbers	863288-34-0, 170851-70-4
Component purity	Typically ≥99% each, per raw-material CoA before blending
Physical form	White lyophilized powder
Additives	None, mannitol-free
Storage	-20°C, sealed, protected from light
Intended use	In-vitro / ex-vivo laboratory research only

Reconstitution & Storage

Both components dissolve readily in aqueous solution, so reconstitution is straightforward.

• Solvent. Sterile water or a suitable aqueous buffer.
• Short-term storage. 2-8°C for reconstituted aliquots.
• Long-term storage. Aliquot, then freeze at -20°C.
• Freeze-thaw. Avoid repeated cycles, since each one costs integrity.

Keep lyophilized material at -20°C and protect it from light. Furthermore, let vials warm to room temperature before opening, because condensation otherwise pulls moisture into the powder. Note that neither component contains methionine or cysteine, so neither requires the inert-atmosphere handling that sulfur-containing peptides benefit from. Otherwise follow your institutional SOPs.

Analytical Documentation

We provide documentation on request for institutional procurement. However, note what a co-lyophilised preparation can and cannot evidence.

• Component purity. Established on raw materials before blending, since HPLC on a finished preparation returns a mixture chromatogram rather than independent per-component figures.
• Identity. Mass spectrometry resolves both component masses, and the 3368 against 712 separation is wide enough to be unambiguous.
• Physical checks. Namely appearance and solubility verification.

Researchers requiring independently verified purity for a single compound should order that compound on its own. Therefore we are happy to quote the standalone components instead where a protocol demands it.

Why Choose Torsena

• Documentation. We send available batch documentation on request.
• No fillers. Mannitol-free, so nothing dilutes the material you paid for.
• EU distribution. We ship from European stock, and therefore intra-EU orders clear no customs.
• Direct contact. You reach the team directly, rather than a ticket queue.

Frequently Asked Questions

What is the difference between CJC-1295 with and without DAC?
The DAC form carries a maleimidopropionyl-lysine group that binds serum albumin, extending half-life to days. The non-DAC form, Modified GRF (1-29), lacks it and clears in roughly 30 minutes, producing pulsatile rather than sustained receptor activation. Structurally they differ by one residue and about 279 Da, so the molecular weight on a CoA distinguishes them: approximately 3368 for non-DAC against approximately 3647 for DAC.

What are the four substitutions in Modified GRF (1-29)?
D-Ala at position 2 blocks DPP-IV cleavage, Gln at position 8 prevents asparagine deamidation, Ala at position 15 enhances bioactivity, and Leu at position 27 removes the oxidation-prone methionine. This is why the compound is often called tetrasubstituted GRF(1-29). Notably the Leu27 change leaves the peptide with no sulfur at all.

Why combine a GHRH agonist with a GHS-R1a agonist?
Because they use different receptors and different second messenger systems. CJC-1295 signals through cAMP and PKA at the GHRH receptor, while Ipamorelin signals through calcium and PKC at GHS-R1a. Published work describes the combined response as exceeding the sum of either alone, since the two pathways converge on somatotroph output without competing.

What makes Ipamorelin selective?
Ipamorelin activates GHS-R1a with minimal effect on ACTH, cortisol or prolactin pathways, which distinguishes it from earlier growth hormone secretagogues that lacked that separation. Consequently it is the usual choice where a protocol needs GHS-R1a engagement without confounding endocrine activity.

Can per-component purity be verified on the blend itself?
No. Reverse-phase HPLC on a co-lyophilised preparation returns a mixture chromatogram, so independent purity figures come from raw-material analysis before blending. Mass spectrometry does resolve both components clearly here, since 3368 and 712 Da are far apart.

Related Research Compounds

Researchers working on growth hormone axis signaling usually look at these as well.

• Tesamorelin. Another GHRH analog, and therefore a direct comparison for GHRH receptor work, though stabilised by N-terminal acylation rather than by substitution.
• Ipamorelin. The standalone pentapeptide, namely where a protocol needs to isolate GHS-R1a engagement.

Otherwise, browse the full catalog at the Torsena shop.